Skip to main content

Market Overview

UPDATE: Oppenheimer Cuts PT to $13 on MAKO Surgical on Lower Procedural Guidance

Share:

Oppenheimer maintained MAKO Surgical (NASDAQ: MAKO) with a Perform rating and lowered the price target from $14.00 to $13.00.

Oppenheimer said, "4Q12 sales of $30.2M were no surprise as MAKO had pre-announced select operating metrics (including soft system placements and procedures) in January. 2013 guidance of 45-48 systems was in-line with our thinking, but light on the procedural side (13,500-14,500 vs our 15,372). Management noted it is hearing some "noise" on new competitive alternatives, but maintains it is not seeing any actual impact to business as a result. Procedure guidance for '13 looks reasonable to us. Visibility on the system guidance is lower, however, owing to competitor counter-detailing and the uncertain macro environment weighing on capex spending decisions. On our lowered '13E sales, our PT moves to $13 from $14."

MAKO Surgical closed at $11.00 on Tuesday.

Latest Ratings for MAKO

DateFirmActionFromTo
Oct 2013PiperJaffrayDowngradesOverweightNeutral
Sep 2013Summer StreetDowngradesBuyNeutral
Sep 2013William BlairDowngradesOutperformMarket Perform

View More Analyst Ratings for MAKO
View the Latest Analyst Ratings

 

Related Articles (MAKO)

View Comments and Join the Discussion!

Posted-In: OppenheimerAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com